(AKBA) Akebia Ther - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 354m USD | Total Return: -14.9% in 12m

Kidney Disease, Anemia, Iron Deficiency
Total Rating 38
Safety 34
Buy Signal -0.90
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3
Market Cap: 354M
Avg Turnover: 3.27M USD
ATR: 5.62%
Peers RS (IBD): 4.0
Risk 5d forecast
Volatility80.9%
Rel. Tail Risk-12.2%
Reward TTM
Sharpe Ratio0.03
Alpha-65.55
Character TTM
Beta1.354
Beta Downside1.653
Drawdowns 3y
Max DD70.57%
CAGR/Max DD0.46
EPS (Earnings per Share) EPS (Earnings per Share) of AKBA over the last years for every Quarter: "2021-03": -0.45, "2021-06": -0.51, "2021-09": -0.34, "2021-12": -0.4, "2022-03": -0.35, "2022-06": 0.23, "2022-09": -0.28, "2022-12": -0.04, "2023-03": -0.14, "2023-06": -0.06, "2023-09": -0.08, "2023-12": 0.0032, "2024-03": -0.09, "2024-06": -0.04, "2024-09": -0.1, "2024-12": -0.1, "2025-03": 0.0247, "2025-06": 0.0267, "2025-09": 0.002, "2025-12": -0.05, "2026-03": 0,
EPS CAGR: -14.58%
EPS Trend: 11.5%
Last SUE: 0.19
Qual. Beats: 0
Revenue Revenue of AKBA over the last years for every Quarter: 2021-03: 52.304, 2021-06: 52.913, 2021-09: 48.756, 2021-12: 57.677, 2022-03: 61.699, 2022-06: 126.365, 2022-09: 48.714, 2022-12: 55.18, 2023-03: 40.005, 2023-06: 56.376, 2023-09: 42.046, 2023-12: 56.196, 2024-03: 32.607, 2024-06: 43.648, 2024-09: 37.428, 2024-12: 46.497, 2025-03: 57.336, 2025-06: 62.472, 2025-09: 58.766, 2025-12: 57.62, 2026-03: null,
Rev. CAGR: -1.81%
Rev. Trend: -19.8%
Last SUE: 0.68
Qual. Beats: 0

Warnings

Share dilution 21.3% YoY - potential capital distress

Interest Coverage Ratio 0.8 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: AKBA Akebia Ther

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company specializing in kidney disease treatments. The companys primary product, Vafseo (vadadustat), is an oral therapy for anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent patients. This drug class, HIF-PHIs, represents a novel approach to anemia management.

Akebia also markets Auryxia, a ferric citrate-based drug for managing phosphorus levels in dialysis patients and treating iron deficiency anemia in non-dialysis CKD patients. The companys pipeline includes earlier-stage candidates for acute kidney injury and retinopathy of prematurity. Biopharmaceutical companies often form strategic partnerships; Akebia has a collaboration with Mitsubishi Tanabe Pharma Corporation for Vafseo in Asian markets.

Further research into Akebias clinical trial data and market position can provide a deeper understanding of its prospects.

Headlines to Watch Out For
  • Vafseo approval and market penetration drives revenue growth
  • Auryxia sales performance impacts profitability
  • Clinical trial success for pipeline assets boosts valuation
  • Regulatory decisions on Vafseo in US market critical
  • Collaboration agreements provide development funding and market access
Piotroski VR‑10 (Strict) 6.0
Net Income: -5.34m TTM > 0 and > 6% of Revenue
FCF/TA: 0.18 > 0.02 and ΔFCF/TA 36.39 > 1.0
NWC/Revenue: 9.27% < 20% (prev 20.55%; Δ -11.28% < -1%)
CFO/TA 0.18 > 3% & CFO 68.0m > Net Income -5.34m
Net Debt (31.5m) to EBITDA (21.7m): 1.45 < 3
Current Ratio: 1.13 > 1.5 & < 3
Outstanding Shares: last quarter (265.4m) vs 12m ago 21.34% < -2%
Gross Margin: 83.29% > 18% (prev 0.72%; Δ 8.26k% > 0.5%)
Asset Turnover: 79.10% > 50% (prev 72.59%; Δ 6.51% > 0%)
Interest Coverage Ratio: 0.85 > 6 (EBITDA TTM 21.7m / Interest Expense TTM 24.2m)
Altman Z'' -15.00
A: 0.06 (Total Current Assets 184.8m - Total Current Liabilities 162.9m) / Total Assets 376.6m
B: -4.47 (Retained Earnings -1.68b / Total Assets 376.6m)
C: 0.07 (EBIT TTM 20.5m / Avg Total Assets 298.6m)
D: -4.90 (Book Value of Equity -1.68b / Total Liabilities 344.0m)
Altman-Z'' Score: -18.87 = D
Beneish M -2.99
DSRI: 0.93 (Receivables 47.0m/34.4m, Revenue 236.2m/160.2m)
GMI: 0.86 (GM 83.29% / 71.57%)
AQI: 1.14 (AQ_t 0.50 / AQ_t-1 0.44)
SGI: 1.47 (Revenue 236.2m / 160.2m)
TATA: -0.19 (NI -5.34m - CFO 68.0m) / TA 376.6m)
Beneish M-Score: -2.99 (Cap -4..+1) = A
What is the price of AKBA shares? As of April 09, 2026, the stock is trading at USD 1.43 with a total of 2,500,698 shares traded.
Over the past week, the price has changed by +1.42%, over one month by +5.93%, over three months by -4.03% and over the past year by -14.88%.
Is AKBA a buy, sell or hold? Akebia Ther has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AKBA.
  • StrongBuy: 3
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AKBA price?
Analysts Target Price 4.4 207.7%
Akebia Ther (AKBA) - Fundamental Data Overview as of 08 April 2026
P/E Forward = 34.4828
P/S = 1.4971
P/B = 11.3362
Revenue TTM = 236.2m USD
EBIT TTM = 20.5m USD
EBITDA TTM = 21.7m USD
Long Term Debt = 48.2m USD (from longTermDebt, last quarter)
Short Term Debt = 43.6m USD (from shortTermDebt, last quarter)
Debt = 216.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.5m USD (from netDebt column, last quarter)
Enterprise Value = 385.1m USD (353.6m + Debt 216.3m - CCE 184.8m)
Interest Coverage Ratio = 0.85 (Ebit TTM 20.5m / Interest Expense TTM 24.2m)
EV/FCF = 5.70x (Enterprise Value 385.1m / FCF TTM 67.6m)
FCF Yield = 17.56% (FCF TTM 67.6m / Enterprise Value 385.1m)
FCF Margin = 28.62% (FCF TTM 67.6m / Revenue TTM 236.2m)
Net Margin = -2.26% (Net Income TTM -5.34m / Revenue TTM 236.2m)
Gross Margin = 83.29% ((Revenue TTM 236.2m - Cost of Revenue TTM 39.5m) / Revenue TTM)
Gross Margin QoQ = 78.80% (prev 83.49%)
Tobins Q-Ratio = 1.02 (Enterprise Value 385.1m / Total Assets 376.6m)
Interest Expense / Debt = 2.23% (Interest Expense 4.83m / Debt 216.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = 16.2m (EBIT 20.5m * (1 - 21.00%))
Current Ratio = 1.13 (Total Current Assets 184.8m / Total Current Liabilities 162.9m)
Debt / Equity = 6.63 (Debt 216.3m / totalStockholderEquity, last quarter 32.6m)
Debt / EBITDA = 1.45 (Net Debt 31.5m / EBITDA 21.7m)
Debt / FCF = 0.47 (Net Debt 31.5m / FCF TTM 67.6m)
Total Stockholder Equity = 32.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.79% (Net Income -5.34m / Total Assets 376.6m)
RoE = -16.70% (Net Income TTM -5.34m / Total Stockholder Equity 32.0m)
RoCE = 25.49% (EBIT 20.5m / Capital Employed (Equity 32.0m + L.T.Debt 48.2m))
RoIC = 20.36% (NOPAT 16.2m / Invested Capital 79.4m)
WACC = 7.34% (E(353.6m)/V(569.9m) * Re(10.75%) + D(216.3m)/V(569.9m) * Rd(2.23%) * (1-Tc(0.21)))
Discount Rate = 10.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.03%
[DCF] Terminal Value 73.84% ; FCFF base≈67.6m ; Y1≈44.4m ; Y5≈20.3m
[DCF] Fair Price = 1.59 (EV 458.0m - Net Debt 31.5m = Equity 426.5m / Shares 267.9m; r=7.34% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 11.52 | EPS CAGR: -14.58% | SUE: 0.19 | # QB: 0
Revenue Correlation: -19.77 | Revenue CAGR: -1.81% | SUE: 0.68 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.030 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.01 | Chg7d=-0.035 | Chg30d=-0.155 | Revisions Net=+1 | Growth EPS=+175.0% | Growth Revenue=-2.0%
EPS next Year (2027-12-31): EPS=-0.10 | Chg7d=-0.070 | Chg30d=-0.300 | Revisions Net=+1 | Growth EPS=-733.3% | Growth Revenue=-16.7%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle